Arcturus Therapeutics Holdings Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joseph E. Payne
- Full Time Employees
- 174
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 10628 Science Center Drive San Diego CA United States of America 92121
- IPO Date
- May 22, 2013
- CIK
- 0001768224
- Website
- arcturusrx.com
- Similar Companies
- Business
- Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) develops and commercializes messenger RNA (mRNA) medicines and vaccines targeting infectious diseases and rare disorders in the liver and respiratory system; its core offerings include self-amplifying mRNA (sa-mRNA) vaccine platforms such as KOSTAIVE, the first approved sa-mRNA COVID-19 vaccine, partnered programs for SARS-CoV-2 and influenza vaccines with CSL Seqirus, and therapeutic candidates like ARCT-810 for ornithine transcarbamylase (OTC) deficiency and ARCT-032 (LunairCF) for cystic fibrosis, leveraging proprietary enabling technologies comprising LUNAR lipid-mediated delivery systems, STARR mRNA technology, and in-house mRNA drug substance and drug product manufacturing. The company's versatile RNA platforms support multiple nucleic acid modalities, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics, protected by an extensive patent portfolio exceeding 500 patents and applications across the U.S., Europe, Japan, China, and other jurisdictions. Founded in 2013 and headquartered in San Diego, California, Arcturus operates globally with significant research, development, manufacturing, and clinical activities in the U.S. and Asia, including a joint venture in Japan called ARCALIS for mRNA vaccine and therapeutic production; it maintains a multicultural team serving patients worldwide through subsidiaries focused on late-stage RNA therapeutics and vaccines. Recent developments encompass the European Commission's approval of KOSTAIVE in February 2025, positive interim Phase 2 data for ARCT-810 in June 2025 demonstrating proof-of-concept in OTC deficiency, interim Phase 2 results for the cystic fibrosis program in October 2025, a strategic prioritization of core mRNA therapeutics for CF and OTC with cost reductions extending cash runway into early 2028 as announced in first-quarter 2025 updates, U.S. FDA Fast Track designation for pandemic influenza candidate ARCT-2304 in April 2025, expansion of San Diego operations, and the appointment of Moncef Slaoui as Chair Designate in February 2025.
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026
Diversify Advisory Services LLC Sells 115,500 Shares of Arcturus Therapeutics Holdings Inc. $ARCT
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Arcturus Therapeutics Refocuses on Rare Disease mRNA Pipeline After COVID Vaccine Success at ROTH Conf
These Are the Only 3 Stocks That Cathie Wood Bought Last Week
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $29.50 Average Target Price from Brokerages
Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing
Arcturus Therapeutics to Attend Upcoming Investor Conference
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025 Earnings Call Transcript
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026
Arcturus Therapeutics Spotlights Inhaled mRNA CF Phase 2b Plan, FDA Talks for OTC Program at Summit
Arcturus Therapeutics: Two Catalysts, One Runway, And A Stock Priced For Failure
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference